| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.090 | AlteredExpression | disease | BEFREE | Eligibility included metastatic prostate cancer and at least one: small-cell neuroendocrine morphology; ≥50% neuroendocrine marker expression; new liver metastases without PSA progression; or elevated serum neuroendocrine markers. | 30232224 | 2019 | ||||
|
0.090 | AlteredExpression | disease | BEFREE | Treatment strategy for metastatic prostate cancer with extremely high PSA level: reconsidering the value of vintage therapy. | 29735818 | 2019 | ||||
|
0.090 | Biomarker | disease | BEFREE | Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages. | 29663462 | 2018 | ||||
|
0.090 | Biomarker | disease | BEFREE | Metastatic prostate cancer in the modern era of PSA screening. | 28338310 | 2017 | ||||
|
0.090 | Biomarker | disease | BEFREE | This could be used to select men for entry at the time of PSA nadir onto randomized trials evaluating the impact on survival of salvage androgen deprivation therapy with or without agents shown to prolong survival in men with castrate-resistant metastatic prostate cancer. | 28097317 | 2017 | ||||
|
0.090 | Biomarker | disease | BEFREE | Patients with PSA value > 4 ng/ml and clinical suspicion of PCa were included. | 29050295 | 2017 | ||||
|
0.090 | Biomarker | disease | BEFREE | Conversion to monotherapy with luteinizing-hormone releasing hormone agonist or orchiectomy after reaching PSA nadir following maximal androgen blockade is able to prolong progression-free survival in patients with metastatic prostate cancer: A propensity score matching analysis. | 28588730 | 2017 | ||||
|
0.090 | Biomarker | disease | BEFREE | C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk. | 19436291 | 2009 | ||||
|
0.090 | AlteredExpression | disease | BEFREE | Thus, this new cell line with partial androgen responsiveness and PSA expression can serve as a functionally relevant model system of bone metastatic prostate cancer, and can be used to investigate the role of AR mutations in prostate cancer and its progression to androgen independence. | 10569618 | 1999 |